OCULAR THERAPEUTIX, INC
About OCULAR THERAPEUTIX, INC
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $52.0M
- Net income
- -$265.9M
- Total assets
- $808.1M
- Market cap
- $1.8B
- Gross margin
- 87.3%
- Operating margin
- -519.8%
- Net margin
- -511.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $52.0M
- Cost of revenue
- $6.6M
- Gross profit
- $45.4M
- Operating expenses
- $315.4M
- Operating income
- -$270.0M
- Income tax
- $0
- Net income
- -$265.9M
- EPS (basic)
- $-1.42
- EPS (diluted)
- $-1.42
Balance sheet
- Total assets
- $808.1M
- Current assets
- $782.1M
- Total liabilities
- $153.7M
- Current liabilities
- $50.8M
- Shareholders’ equity
- $654.3M
Cash flow
- Operating cash flow
- -$204.9M
- Investing cash flow
- -$11.9M
- Financing cash flow
- $561.7M
- Net cash flow
- $345.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.8B
- EPS (diluted)
- $-1.42
- Shares outstanding
- 221.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 25, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $265.9M in FY2025.
- Revenue grew 199% from FY2020 to FY2025.
- Gross margin of 87.3%, net margin -511.9%.
- Trading 49% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review OCULAR THERAPEUTIX, INC.
Write a review
News about OCULAR THERAPEUTIX, INC
News & sentiment via Polygon.io
